Novo Nordisk A/S (NONOF)
| Market Cap | 276.62B |
| Revenue (ttm) | 40.31B |
| Net Income (ttm) | 14.02B |
| Shares Out | n/a |
| EPS (ttm) | 3.14 |
| PE Ratio | 19.73 |
| Forward PE | n/a |
| Dividend | 1.66 (2.70%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 300 |
| Average Volume | 103,170 |
| Open | 63.55 |
| Previous Close | 61.50 |
| Day's Range | 61.55 - 63.55 |
| 52-Week Range | 55.28 - 149.55 |
| Beta | 0.25 |
| RSI | 38.27 |
| Earnings Date | May 7, 2025 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsNews
Novo Nordisk's stellar Wegovy-fuelled run of hiking sales guidance could be ending
Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several times a year.
Chart Master: Sell Morgan Stanley, buy Novo Nordisk?
Carter Worth, Worth Charting, talks technicals on Morgan Stanley and Novo Nordisk.
Chart Master: Sell Morgan Stanley, buy Novo Nordisk?
Carter Worth, Worth Charting, talks technicals on Morgan Stanley and Novo Nordisk.
SAP soars most in six years after profit beats estimates
SAP's stock has risen 36% over the last year and its value eclipsed Novo Nordisk and LVMH in March.
Novo Nordisk Investors Just Got Terrible News. Should You Sell the Stock?
Eris Lifesciences, Lupin and Biocon shares in focus as Novo Nordisk exits Rs 800 crore Human Mixtard brand, says report
Shares of Eris Lifesciences, Lupin, and Biocon were in focus on April 23 after pharmaceutical major Novo Nordisk announced the discontinuation of its Human Mixtard insulin brand in India — one of the ...
Eris Lifesciences shares surge over 4% as Novo Nordisk reportedly exits Human Mixtard insulin market in India
Shares of Eris Lifesciences Ltd climbed 4.19% to ₹1,458 in early trade on April 23 after Novo Nordisk reportedly announced its decision to phase out Human Mixtard—India’s largest-selling insulin brand...
Novo Nordisk's Options Frenzy: What You Need to Know
Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE: NVO) revealed 15 unusual trades. Delving into the details, we found 46% ...
Novo Nordisk Just Leapfrogged Eli Lilly With A Weight-Loss Pill; Shares Pop
Novo Nordisk stock popped Tuesday on reports it's asked the FDA to approve its weight-loss pill, an oral version of Wegovy.
Novo Nordisk: Be Greedy When Others Are Fearful
Novo Nordisk's booming obesity drugs & diabetes portfolio make it a top growth play.
Think It's Too Late to Buy Novo Nordisk? Here's the Biggest Reason Why There's Still Time.
Novo Nordisk slides after Eli Lilly's results for oral weight loss drug—orforglipron
Novo Nordisk Shares Fall After Data From New Eli Lilly Pill
Shares fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant's blockbuster shots.
Novo Nordisk slides on pressure from Lilly’s pill study
The Eli Lilly & Co. study puts pressure on Novo, whose market value has dropped by a third since the start of the year.
Is Novo Nordisk falling behind Eli Lilly in the weight-loss drug race?
Danish drugmaker Novo Nordisk A/S (CPH: NOVO-B) lost more than 10% last week after its US rival Eli Lilly & Co (NYSE: LLY) reported encouraging Phase 3 data for its oral weight-loss treatment. Lilly'...
5 European stocks to watch this earnings season as Trump's tariffs hit
The scale of President Donald Trump's tariffs, along with the volatility injected by subsequent updates and reversals in policy, have so far exceeded even the most bearish forecasts. Danish shipping g...
Novo Nordisk has sought approval of oral version of Wegovy - report
LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed
The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.
Did Eli Lilly Just Say Checkmate to Novo Nordisk?
Selling America, Buying Europe - My Picks
After years of strong returns, amidst the tariff-induced uncertainty, I am rotating towards European-based equities. US economy is facing mounting pressures, via weakening consumer demand, reduced CAP...
Novo Nordisk: Why I Love Collars, And Why This Stock Is Getting Close
Novo Nordisk (NVO) Downgraded Amid Rising Competition from Eli Lilly
Novo Nordisk (NVO) Downgraded Amid Rising Competition from Eli Lilly
Novo Nordisk: A Price Too Low To Ignore
Netflix, UnitedHealth, Novo Nordisk, Tesla And Trump Media: Why These 5 Stocks Are On Investors' Radars Today
Wall Street experienced a resurgence in risk appetite on Thursday as optimism grew around trade negotiations. President Donald Trump expressed confidence in reaching agreements with both the European ...
Eli Lilly Rallies Over 14%, Notches Best Day Since June 2000 On Oral Weight-Loss Drug Results: Analysts React
Eli Lilly & Co. (NYSE: LLY) shares staged their sharpest single-day rally in nearly 25 years Thursday, after unveiling data from a pivotal trial that could cement its leadership in a weight-loss drug...